ReviewhLife2026
Diagnostics for human pathogenic fungal infections: Current status and future prospects.
Review in hLife, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human fungal infections represent a rapidly emerging global health threat, especially threatening immunocompromised populations, highlighting the urgent need for accurate and timely diagnostic approaches to reduce morbidity and mortality. This review synthesizes recent advances in diagnostic methodologies, including serological assays, point-of-care diagnostics, polymerase chain reaction (PCR)-based and sequencing technologies, as well as artificial intelligence (AI)- and machine learning (ML)-powered tools. Emerging diagnostic approaches have demonstrated notable improvements in detection accuracy, turnaround time, and antifungal resistance profiling capabilities, especially for drug-resistant strains. Nevertheless, substantial challenges persist in terms of standardization, scalability, cost-effectiveness, and implementation, particularly in resource-constrained settings. Future efforts should be directed toward the continuous innovation of rapid, sensitive, and multiplex diagnostic platforms for the simultaneous detection of fungi, bacteria, and viruses. Such advances may accelerate result acquisition, enhance diagnostic accuracy, support the development of more targeted therapeutic strategies, and ultimately improve clinical outcomes for patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.